Recordati has licensed Ionis’s experimental RNA-based drug zilganersen (targeting Alexander disease) for exclusive ex-U.S. development and commercialization. Under the licensing agreement announced June 25, 2026, Ionis receives a $30 million upfront payment, additional milestone payments, and tiered royalties of up to the mid‐20% range on annual net sales. Ionis retains sole U.S. commercial rights and leads global development, while Recordati will manage regulatory filings and commercialization in all other countries. Vaxart’s BARDA funding cut refers to BARDA eliminating $100 million in funding earmarked for Vaxart’s norovirus vaccine program, effectively halting that specific BARDA-supported project. Sources: Ionis announces license agreement with Recordati for zilganersen ... Ionis licenses zilganersen to Recordati for ex-U.S. markets Recordati signs new Ionis licensing deal, shares trade steadily in ... Ionis, Recordati Ink $30M Zilganersen Deal - AllSci [PDF] PEO...
- Get link
- X
- Other Apps